As the General Manager, Oncology Business Unit, China, I am working to drive strategic and operational alignment for all oncology brands in China. Our goal is to continuously offer innovative solutions to meet the unmet needs of people living with cancer.

I am committed to improving patient outcomes, and feel an enormous sense of achievement when we work together with our partners to provide important medicines and holistic disease management solutions.

I have been with AstraZeneca for more than 15 years, serving in multiple functions and geographies. Prior to my current role, I held various positions of increasing responsibility within Finance, Compliance and Commercial.  

Before joining AstraZeneca, I served in the Finance and Human Resources Department at Eli Lilly in China. I also previously served as co-chairman of the Compliance & Legal workstream of the R&D-based Pharmaceutical Association Committee, China Association of Enterprise with Foreign Investment (RDPAC), and Vice President of the China Association of Pharmaceutical Commerce.

I received my MBA from the China Europe International Business School and completed the exchange program at London Business School. I also hold degrees in Finance & Trading and Computer Science from Shanghai Jiao Tong University.  

In China, cancer remains a leading cause of death and a major public health concern. Our team is fully committed to helping prolong survival rates and improve the quality of life of cancer patients by delivering innovative medicines and increasing awareness of cancer prevention, early screening and diagnosis.

Eva Yin General Manager, Oncology Business Unit

Award icon


2018-2021: Successfully led teams to win several CEO Awards, Oncology Business Unit Awards, International EVP Awards and China President Awards within AstraZeneca


General Manager, Oncology Business Unit

China OBU portfolio

Successfully lead the China OBU and its portfolio with positive year-over-year growth

Cancer prevention programmes

Turned the concept of ‘cancer prevention’ into practice through sponsoring third-party projects, such as lung cancer early screening and prostate cancer PSA screening

General Manager of AstraZeneca HK & Macau (2017-2018)

Led the team to dedicate to the HK & Macau life-sciences industry